• Publications
  • Influence
Gene therapy finds its niche
  • C. Sheridan
  • Biology, Medicine
  • Nature Biotechnology
  • 7 February 2011
Gene therapy is finally poised to make a contribution to the treatment of debilitating, highly penetrant genetic diseases that have proved intractable to other regimens.
Fast, portable tests come online to curb coronavirus pandemic
  • C. Sheridan
  • Medicine, Geography
  • Nature Biotechnology
  • 23 March 2020
TLDR
Testing kits delivered by courier and digital tools combine to battle the COVID-19 outbreak to find out which kits are most effective in protecting against infection. Expand
First Axl inhibitor enters clinical trials
  • C. Sheridan
  • Medicine, Biology
  • Nature Biotechnology
  • 10 September 2013
TLDR
It is shown that people who self-identified as seekers of happiness through living a life of purpose have a gene expression profile favorable to the immune system, whereas hedonistic people, while claiming to be happy, had negative expression profiles. Expand
Coronavirus and the race to distribute reliable diagnostics
  • C. Sheridan
  • Medicine
  • Nature Biotechnology
  • 19 February 2020
TLDR
International teams worked at speed to make tests for the virus available in record time, with results shown in less than a minute. Expand
Illumina claims $1,000 genome win
  • C. Sheridan
  • Biology, Medicine
  • Nature Biotechnology
  • 7 February 2014
TLDR
Drug developers are mounting a poly(ADPribose) polymerase (PARP) inhibitor comeback, and a few are now experimenting with a more comprehensive companion diagnostic to smooth the way, with more imminent competition to Imbruvica likely to come from newer, targeted agents in late-stage development, especially in CLL. Expand
J&J's billion dollar punt on anti-amyloid antibody
  • C. Sheridan
  • Biology, Medicine
  • Nature Biotechnology
  • 1 August 2009
TLDR
A negative result would be a significant setback for the field, after the recent failures of two other anti-amyloid drugs, the gamma secretase inhibitor Flurizan and Alzhemed, which were designed to prevent beta amyloid aggregation. Expand
Amgen's angiopoietin blocker fails in ovarian cancer
  • C. Sheridan
  • Medicine, Biology
  • Nature Biotechnology
  • 9 January 2015
TLDR
Although trebananib has definite biological effects, a precise understanding of its mechanism remains elusive, which may have led to its deployment in settings in which its performance was suboptimal, and could have a chilling effect on some drug developers investing in similar molecules. Expand
Europe lags, US leads 2nd-generation biofuels
  • C. Sheridan
  • Medicine, Biology
  • Nature Biotechnology
  • 1 December 2008
First cystic fibrosis drug advances towards approval
  • C. Sheridan
  • Biology, Medicine
  • Nature Biotechnology
  • 7 June 2011
TLDR
The first disease-modifying therapy for cystic fibrosis could reach the market next year, following the publication of highly promising data from two phase 3 trials in recent months, and marks the beginning of a new era of small-molecule drugs that could profoundly change the course of therapy for the vast majority of individuals with the disease. Expand
TeGenero fiasco prompts regulatory rethink
The catastrophic phase 1 clinical trial of German biotech TeGenero's monoclonal antibody designed to activate the immune system's T cells has raised serious concerns about the adequacy of theExpand
...
1
2
3
4
5
...